Page last updated: 2024-10-25

cilostazol and Atrial Fibrillation

cilostazol has been researched along with Atrial Fibrillation in 7 studies

Atrial Fibrillation: Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.

Research Excerpts

ExcerptRelevanceReference
"We hypothesized that administration of cilostazol may clarify the occult atrial fibrillation (AF) during hospitalization in mild stroke patients, who has no history of AF."9.34Cilostazol uncovers covert atrial fibrillation in non-cardioembolic stroke. ( Abe, K; Aoki, J; Fujimoto, S; Idomari, K; Iguchi, Y; Inoue, T; Iwanaga, T; Kaneko, N; Kimura, K; Matsuoka, H; Nomura, K; Okada, Y; Tanaka, R; Terasaki, T; Todo, K; Tsujino, A; Uno, M; Urabe, T; Yagita, Y; Yamagami, H; Yamagata, S; Yamamoto, N; Yamamoto, Y; Yonehara, T, 2020)
"Randomised trials have shown the efficacy of antiplatelet therapy with cilostazol to prevent secondary ischaemic stroke."7.81Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy. ( Hayashi, K; Horie, N; Izumo, T; Kaminogo, M; Nagata, I; Tsujino, A, 2015)
"Twelve patients (6 males and 6 females) with bradycardiac atrial fibrillation underwent Holter monitoring (24-hour total heartbeat counts and frequency of pause), echocardiography (left ventricular end-diastolic diameter, percentage fractional shortening), chest roentgenography (cardiothoracic ratio), and measurements of brain natriuretic peptide and atrial natriuretic peptide before and 6 months after daily oral administration of 100-200 mg cilostazol."7.71[Effects of cilostazol in patients with bradycardiac atrial fibrillation]. ( Kishida, M; Tsuruoka, T; Watanabe, K, 2001)
" We examined the effects of cilostazol, a quinolinone derivative, on HR and HR variability in patients with chronic atrial fibrillation associated with bradycardia episodes."7.70Effects of cilostazol on heart rate and its variation in patients with atrial fibrillation associated with bradycardia. ( Kanai, H; Kusachi, S; Mashima, K; Murakami, T; Nakatsu, T; Tominaga, Y; Toyonaga, S; Tsuji, T; Uesugi, T; Yamane, S, 2000)
"We hypothesized that administration of cilostazol may clarify the occult atrial fibrillation (AF) during hospitalization in mild stroke patients, who has no history of AF."5.34Cilostazol uncovers covert atrial fibrillation in non-cardioembolic stroke. ( Abe, K; Aoki, J; Fujimoto, S; Idomari, K; Iguchi, Y; Inoue, T; Iwanaga, T; Kaneko, N; Kimura, K; Matsuoka, H; Nomura, K; Okada, Y; Tanaka, R; Terasaki, T; Todo, K; Tsujino, A; Uno, M; Urabe, T; Yagita, Y; Yamagami, H; Yamagata, S; Yamamoto, N; Yamamoto, Y; Yonehara, T, 2020)
"Our results showed that 200 mg cilostazol treatment decreased TACT duration in patients with peripheral artery disease, which may also prevent the development and/or recurrence of atrial fibrillation (AF)."5.19Cilostazol decreases total atrial conduction time in patients with peripheral artery disease. ( Açar, G; Akçakoyun, M; Alizade, E; Avcı, A; Bulut, M; Esen, AM; Güler, A; Kalkan, ME; Pala, S; Sahin, M; Simşek, Z, 2014)
"The role of aspirin in the early management of stroke is well established."4.89Pharmacokinetic considerations for antithrombotic therapies in stroke. ( Apostolakis, S; Lip, GY; Shantsila, E, 2013)
"Randomised trials have shown the efficacy of antiplatelet therapy with cilostazol to prevent secondary ischaemic stroke."3.81Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy. ( Hayashi, K; Horie, N; Izumo, T; Kaminogo, M; Nagata, I; Tsujino, A, 2015)
"Twelve patients (6 males and 6 females) with bradycardiac atrial fibrillation underwent Holter monitoring (24-hour total heartbeat counts and frequency of pause), echocardiography (left ventricular end-diastolic diameter, percentage fractional shortening), chest roentgenography (cardiothoracic ratio), and measurements of brain natriuretic peptide and atrial natriuretic peptide before and 6 months after daily oral administration of 100-200 mg cilostazol."3.71[Effects of cilostazol in patients with bradycardiac atrial fibrillation]. ( Kishida, M; Tsuruoka, T; Watanabe, K, 2001)
" We examined the effects of cilostazol, a quinolinone derivative, on HR and HR variability in patients with chronic atrial fibrillation associated with bradycardia episodes."3.70Effects of cilostazol on heart rate and its variation in patients with atrial fibrillation associated with bradycardia. ( Kanai, H; Kusachi, S; Mashima, K; Murakami, T; Nakatsu, T; Tominaga, Y; Toyonaga, S; Tsuji, T; Uesugi, T; Yamane, S, 2000)

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (14.29)18.2507
2000's2 (28.57)29.6817
2010's3 (42.86)24.3611
2020's1 (14.29)2.80

Authors

AuthorsStudies
Aoki, J1
Iguchi, Y1
Urabe, T1
Yamagami, H1
Todo, K1
Fujimoto, S1
Idomari, K1
Kaneko, N1
Iwanaga, T1
Terasaki, T1
Tanaka, R1
Yamamoto, N1
Tsujino, A2
Nomura, K1
Abe, K1
Uno, M1
Okada, Y1
Matsuoka, H1
Yamagata, S1
Yamamoto, Y1
Yonehara, T1
Inoue, T1
Yagita, Y1
Kimura, K1
Apostolakis, S1
Lip, GY1
Shantsila, E1
Alizade, E1
Sahin, M1
Simşek, Z1
Açar, G1
Bulut, M1
Güler, A1
Avcı, A1
Kalkan, ME1
Pala, S1
Akçakoyun, M1
Esen, AM1
Horie, N1
Kaminogo, M1
Izumo, T1
Hayashi, K1
Nagata, I1
Atarashi, H1
Endoh, Y1
Saitoh, H1
Kishida, H1
Hayakawa, H1
Toyonaga, S1
Nakatsu, T1
Murakami, T1
Kusachi, S1
Mashima, K1
Tominaga, Y1
Yamane, S1
Uesugi, T1
Kanai, H1
Tsuji, T1
Kishida, M1
Watanabe, K1
Tsuruoka, T1

Reviews

1 review available for cilostazol and Atrial Fibrillation

ArticleYear
Pharmacokinetic considerations for antithrombotic therapies in stroke.
    Expert opinion on drug metabolism & toxicology, 2013, Volume: 9, Issue:10

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Cilostazol; Clopidogrel; Factor

2013

Trials

3 trials available for cilostazol and Atrial Fibrillation

ArticleYear
Cilostazol uncovers covert atrial fibrillation in non-cardioembolic stroke.
    Journal of the neurological sciences, 2020, 06-15, Volume: 413

    Topics: Aged; Atrial Fibrillation; Cilostazol; Humans; Male; Prospective Studies; Retrospective Studies; Ris

2020
Cilostazol decreases total atrial conduction time in patients with peripheral artery disease.
    Perfusion, 2014, Volume: 29, Issue:3

    Topics: Aged; Atrial Fibrillation; Cilostazol; Female; Follow-Up Studies; Humans; Male; Middle Aged; Periphe

2014
Chronotropic effects of cilostazol, a new antithrombotic agent, in patients with bradyarrhythmias.
    Journal of cardiovascular pharmacology, 1998, Volume: 31, Issue:4

    Topics: Administration, Oral; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Atrial Fibrillation; Bradycardi

1998

Other Studies

3 other studies available for cilostazol and Atrial Fibrillation

ArticleYear
Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy.
    Neurological research, 2015, Volume: 37, Issue:7

    Topics: Aged; Aspirin; Atrial Fibrillation; Cilostazol; Clopidogrel; Databases, Factual; Female; Fibrinolyti

2015
Effects of cilostazol on heart rate and its variation in patients with atrial fibrillation associated with bradycardia.
    Journal of cardiovascular pharmacology and therapeutics, 2000, Volume: 5, Issue:3

    Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Atrial Natriuretic Factor; Bradycardia; Cilostazol; Ci

2000
[Effects of cilostazol in patients with bradycardiac atrial fibrillation].
    Journal of cardiology, 2001, Volume: 37, Issue:1

    Topics: Aged; Atrial Fibrillation; Atrial Natriuretic Factor; Blood Pressure; Bradycardia; Cilostazol; Drug

2001